Opioid and non-opioid analgesic prescribing before and after the CDC’s 2016 opioid guideline
Tóm tắt
The U.S. has addressed the opioid crisis using a two-front approach: state regulations limiting opioid prescriptions for acute pain patients, and voluntary federal CDC guidelines on shifting chronic pain patients to lower opioid doses and non-opioids. No opioid policy research to date has accounted for this two-pronged approach in their research design. We develop a theory of physician prescribing behavior under this two-pronged incentive structure. Using the Medical Expenditure Panel Survey, we empirically corroborate the theory: regulations and guidelines have the intended effects of reducing opioid prescriptions for acute and chronic pain, respectively, as well as the predicted unintended effects—income effects cause regulations on acute pain treatment to increase chronic pain opioid prescriptions and the chronic pain treatment guidelines spillover to reduce opioids for acute pain. Moreover, we find that the guidelines worked as intended in terms of the reduced usage, with chronic pain patients shifting to non-opioids and also tapering opioid doses. For those who discontinued opioids under regulations and guidelines, we find no harm in terms of increased work limitations due to pain a year after discontinuing opioids. Finally, we observe an unexplained dichotomy—regulations reduce opioid use by causing fewer new starts, whereas guidelines reduce opioid use by discontinuing current users, with no impact on new starts.
Tài liệu tham khảo
Adams, J. M., & Giroir, B. P. (2019). Opioid prescribing trends and the Physician’s role in responding to the public health crisis. JAMA Internal Medicine, 179(4), 476–478.
Agency for Healthcare Research and Quality. (2020a). Nonopioid pharmacologic treatments for chronic pain. Research Protocol. Rockville, MD: https://effectivehealthcare.ahrq.gov/products/nonopioid-chronic-pain/protocol (accessed 11 Mar 2020).
Agency for Healthcare Research and Quality. (2020b). About the six building blocks program. Rockville, MD. https://www.ahrq.gov/professionals/prevention-chronic-care/improve/six-building-blocks.html (accessed 11 Mar 2020).
Alghnam, S., & Castillo, R. (2017). Traumatic injuries and persistent opioid use in the USA: Findings from a nationally representative survey. Injury Prevention, 23, 87–92.
Baker, D. W. (2017). The Joint Commission’s pain standards: origins and evolutions. The Joint Commission.
Ballantyne, J. C., & Sullivan, M. D. (2015). Intensity of chronic pain—the wrong metric. New England Journal of Medicine, 373(22), 2098–2099.
Bao, Y., Wen, K., Johnson, P., Jeng, P. J., Meisel, Z. F., & Schackman, B. R. (2018). Assessing the impact of state policies for prescription drug monitoring programs on high-risk opioid prescriptions. Health Affairs, 37(10), 1596–1604.
Bernard, D., Encinosa, W., Cohen, J., & Fang, Z. (2020). Patient factors that affect opioid use among adults with and without chronic pain. Research in Social and Administrative Pharmacy. https://doi.org/10.1016/j.sapharm.2020.07.036
Bernard, D., Machlin, S. R., Fang, Z., & Cohen, J. (2019). Average annual opioid use among adults treated for conditions associated with chronic pain versus other conditions, 2013–2015. Research Findings #43. Agency for Healthcare Research and Quality, Rockville, MD. https://meps.ahrq.gov/data_files/publications/rf43/rf43.pdf (accessed 11 Mar 2020).
Bohnert, A. S., Guy, G. P., Jr., & Losby, J. L. (2018). Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention’s 2016 opioid guideline. Annals of Internal Medicine, 169(6), 367–375.
Brat, G. A., Agniel, D., Beam, A., et al. (2018). Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: Retrospective cohort study. BMJ, 360, j5790.
Brennan, F. (2015). The US congressional “Decade on Pain Control and Research” 2001–2011: A review. Journal of Pain and Palliative Care Pharmacotherapy, 29(3), 212–227.
Califf, R. M., Woodcock, J., & Stephen Ostroff, S. (2016). A proactive response to prescription opioid abuse. New England Journal of Medicine, 14(374), 1480–1485.
Centers for Disease Control and Prevention. (2017). Vital Signs. Opioid prescribing where you live matters. https://www.cdc.gov/vitalsigns/opioids/index.html
Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. (2020). U.S. Opioid Dispensing Rate Maps. Dec 7, 2020 https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html
Chou, R., Deyo, R., Devine, B., Hansen, R., Sullivan, S., Jarvik, J. G., Blazina, I., Dana, T., Bougatsos, C., Turner, J. (2014). The effectiveness and risks of long-term opioid treatment of chronic pain [Evidence Report/Technology Assessment No. 218]. Agency for Healthcare Research and Quality. http://www.effectivehealthcare.ahrq.gov/ehc/products/557/1971/chronic-pain-opioid-treatment-report-141007.pdf (accessed 31 Jan 2020).
Chou, R., Turner, J. A., Devine, E. B., et al. (2015). The effectiveness and risks of long-term opioid therapy for chronic pain: A systematic review for a National Institutes of Health Pathways to Prevention Workshop. Annals of Internal Medicine, 162, 276–286.
Chua, K.-P. & Kimmel, L. (2020). Opioid Prescribing limits for acute pain. Institute for Healthcare Policy and Innovation, University of Michigan. https://effectivehealthcare.ahrq.gov/products/chronicpain-opioid-treatment/research.
Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014). The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. JAMA Psychiatry, 71(7), 821–826.
Cohen, S. (2000). Sample Design of the 1997 medical expenditure panel survey household component, methodology report 11, AHRQ Pub. No. 01–0001. Rockville (MD): Agency for Healthcare Research and Quality.
Compton, W. M., & Jones, C. M. (2019). Epidemiology of the US opioid crisis: The importance of the vector. Annals of the New York Academy of Sciences, 1451(1), 130–143.
Council of Economic Advisors. (2019). The full cost of the opioid crisis: $2.5 Trillion over 4 years. https://trumpwhitehouse.archives.gov/articles/full-cost-opioid-crisis-2-5-trillion-four-years/
Council of Economic Advisors. (2020). The economic report of the President. Feb 2020. https://www.nber.org/sites/default/files/2020-05/ERP-2020.pdf
Currie, J. & Schwandt, H. H. (2020). The Opioid epidemic was not caused by economic distress but by factors that could be more rapidly addressed. NBER Working Paper 27544.
Dasgupta, N., Beletsky, L., & Ciccarone, D. (2018). Opioid crisis: No easy fix to its social and economic determinants. AJPH, 108(2), 182–186.
Davis, C. S., Lieberman, A. J., Hernandez-Delgado, H., & Suba, C. (2019). Laws limiting the prescribing or dispensing of opioids for acute pain in the United States: A national systematic legal review. Drug and Alcohol Dependence, 194, 166–172.
Delcher, C., Slavova, S., Wang, Y. M. S., & Henry, S. G. (2019). Opioid prescribing before and after the Centers for disease control and prevention’s 2016 opioid guideline, letter to the editor. Annals of Internal Medicine, 170(8), 581–582.
Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA, 315(15), 1624–1645.
Dowell, D., Haegerich, T., & Chou, R. (2019). No shortcuts to safer opioid prescribing. New England Journal of Medicine, 380(24), 2285–2287.
Edlund, M. J., Martin, B. C., Russo, J. E., DeVries, A., Braden, J. B., & Sullivan, M. D. (2014). The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: The role of opioid prescription. Clinical Journal of Pain, 30(7), 557–564.
Ellis, R., & McGuire, T. (1986). Provider behavior under prospective reimbursement: Cost sharing and supply. Journal of Health Economics, 5, 129–151.
Hedegaard, H., Miniño, A. M., & Warner, M. (2020). Drug overdose deaths in the United States, 1999–2019. NCHS Data Brief, no. 394. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; https://www.cdc.gov/nchs/data/databriefs/db394-H.pdfpdf icon.
Haffajee, R. L., Mello, M. M., Zhang, F., Zaslavsky, A. M., Larochelle, M. R., & Wharam, J. F. (2018). Four states with robust prescription drug monitoring programs reduced opioid dosages. Health Affairs, 37(6), 964–974.
Heins, S. E., Feldman, D. R., Bodycombe, D., et al. (2016). Early opioid prescription and risk of long-term opioid use among US workers with back and shoulder injuries: A retrospective cohort study. Injury Prevention, 22, 211–215.
Hill, S.C., Roemer, M., Stagnitti, M.N. (2014) Outpatient prescription drugs: Data Collection and editing in the 2011 medical expenditure panel survey. Methodology Report #29. March 2014. Agency for Healthcare Research and Quality, Rockville, MD. http://meps.ahrq.gov/mepsweb/data_files/publications/mr29/mr29.pdf (accessed 11 Mar 2020).
Hincapie-Castillo, J. M., Goodin, M., Possinger, M.-C., Usmani, S. A., & Vouri, S. M. (2020). Changes in opioid use after Florida’s restriction law for acute pain prescriptions. JAMA Network Open, 3(2), e2002.
Hoppe, J. A., Howard, K., & Kennon, H. (2015). Association of emergency department opioid initiation with recurrent opioid use. Annals of Emergency Medicine, 65, 493–499.
Jones, C. M. (2013). Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers—United States, 2002–2004 and 2008–2010. Drug and Alcohol Dependence, 132(1–2), 95–100.
Kaestner, R. & Ziedan E. (2019). Mortality and socioeconomic consequences of prescription opioids: Evidence from state policies. National Bureau of Economic Research. Cambridge, MA: Working Paper 26135.
Kang, N. (2020). Once The coronavirus pandemic subsides, the opioid epidemic will rage. Health Affairs Blog, April 15, 2020.
Keefe, P. R. (2017). The family that built an empire of pain. The New Yorker. 17 Oct 2017.
Lankenau, S. E., Teti, M., Silva, K., Bloom, J. J., Harocopos, A., & Treese, M. (2012). Initiation into prescription opioid misuse amongst young injection drug users. The International Journal on Drug Policy, 23(1), 37–44.
Maclean, J. C., Mallatt, J., Ruhm C. J. & Simon, K. (2020). Economic studies on the opioid crisis: A review. NBER Working paper 28067.
Manchikanti, L., Kaye, A. M., Knezevic, N. N., et al. (2017). Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician, 20(2S), S3–S92.
Mattson, C. L., Tanz, L. J., Quinn, K., Kariisa, M., Patel, P., & Davis, N. L. (2021). Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. Morbidity and Mortality Weekly Report, 70(6), 202–207. https://doi.org/10.15585/mmwr.mm7006a4
Max, M. B. (1990). Improving outcomes of analgesic treatment: Is education enough? Annals of Internal Medicine, 113(11), 885–889.
McGuire, T. G., & Pauly, M. V. (1991). Physician response to fee changes with multiple payers. Journal of Health Economics, 10(4), 385–410. https://doi.org/10.1016/0167-6296(91)90022-f PMID: 10117011.
Mezei, L., & Murinson, B. B. (2011). Pain education in North American medical schools. The Journal of Pain, 12, 1199–1208.
Muhuri, P. K., Gfroerer, J. C., & Davies, M. C. (2013). Substance abuse and mental health services administration. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review. Accessed October 8, 2015. https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm
Olaughlin, C., & Brantlye, K. (2018). Trends in opioid Use: History, background, and origins of the epidemic. Avalere Health. https://avalere.com/insights/trends-in-opioid-use-history-background-and-origins-of-the-epidemic (Accessed 11 Nov 2019).
Olfson, M., Wang, S., Wall, M. M., & Blanco, C. (2020). Trends in opioid prescribing and self-reported pain among US adults. Health Affairs (millwood), 39(1), 146–154.
Paulozzi, L. J., Zhang, K., Jones, C. M., & Mack, K. A. (2014). Risk of adverse health outcomes with increasing duration and regularity of opioid therapy. Journal of the American Board of Family Medicine, 27(3), 329–338.
Perry, S., & Heidrich, G. (1982). Management of pain during debridement: A survey of US burn units. Pain, 13, 267–280.
Porter, J., & Jick, H. (1980). Addiction rare in patients treated with narcotics. New England Journal of Medicine, 302, 1.
National Conference of State Legislatures. (2019). Prescribing Policies: States confront opioid overdose epidemic. Washington, DC. www.ncsl.org/research/health/prescribing-policies-states-confront-opioid-overdose-epidemic.aspx (Accessed 9 Sept 2019).
Rosenberg, J. M., Bilka, B. M., Wilson, S. M., & Spevak, C. (2018). Opioid therapy for chronic pain: Overview of the 2017 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline. Pain Medicine, 19(5), 928–941. https://doi.org/10.1093/pm/pnx203
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016). Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR. Morbidity and Mortality Weekly Report, 65(50–51), 1445–1452.
Rutkow, L., & Vernick, J. S. (2017). more states should regulate pain management clinics to promote public health. AJPH, 107(2), 240–243.
Ryder, S.-A., & Stannard, C. F. (2005). Treatment of chronic pain: Antidepressant, antiepileptic and antiarrhythmic drugs. Continuing Education. Anaesthesia, Critical Care and Pain, 5(1), 18–21.
Sacks, D. W., Hollingsworth, A., Nguyen, T. D., & Simon, K. I. (2019). Can policy affect initiation of addictive substance use? Evidence from opioid prescribing. Cambridge, MA: NBER Working Paper No. 25974.
Schieber, L. Z., Guy, G. P., Seth, P., Young, R., Mattson, C. L., Mikosz, C. A., & Schieber, R. A. (2019). Trends and Patterns of geographic variation in opioid prescribing practices by State, United States, 2006–2017. JAMA Network Open, 2(3), e190665.
Scholl, L., Seth, P., Kariisa, M., Wilson, N., & Baldwin, G. (2019). Drug and opioid-involved overdose deaths—United States, 2013–2017. Morbidity and Mortality Weekly Report, 67(51–52), 1419. https://doi.org/10.15585/mmwr.mm675152e1
Schuchat, A., Houry, D., & Guy, G. P. (2017). New data on opioid use and prescribing in the United States. JAMA, 318(5), 425–426. https://doi.org/10.1001/jama.2017.8913
Shah, A., Hayes, C. J., & Martin, B. C. (2017). Characteristics of initial prescription episodes and likelihood of long-term opioid use: United States, 2006–2015. Morbidity and Mortality Weekly Report, 66(10), 265–269.
Song, Z. (2017). Mortality Quadrupled among opioid-driven hospitalizations, notably within lower-income and disabled white populations. Health Affairs, 36(12), 2054–2061.
Tian, T. Y., Zlaveta, I., & Anderson, D. R. (2013). Using electronic health records data to identify patients with chronic pain in a primary care setting. Journal of the American Medical Informatics Association, 20(e2), e275–e280.
Van Zee, A. (2009). The promotion and marketing of oxycontin: Commercial triumph, public health tragedy. American Journal of Public Health, 99(2), 221–227.
Vowles, K. E., McEntee, M. L., Julnes, P. S., Frohe, T., Ney, J. P., & van der Goes, D. N. (2015). Rates of opioid misuse, abuse, and addiction in chronic pain: A systematic review and data synthesis. Pain, 156(4), 569–576. https://doi.org/10.1097/01.j.pain.0000460357.01998.f1
Wen, H., Hockenberry, M., Jeng, P. J., & Bao, Y. (2019). Prescription drug monitoring program mandates: Impact on opioid prescribing and related hospital use. Health Affairs, 38(9), 1550–1556.
Wen, H., Schackman, B. R., Aden, B., & Bao, Y. (2017). States with prescription drug monitoring mandates saw a reduction in opioids prescribed to Medicaid enrollees. Health Affairs, 36(4), 733–741.
Yanni, L. M., McKinney-Ketchum, J. L., Harrington, S. B., et al. (2010). Preparation, confidence, and attitudes about chronic noncancer pain in graduate medical education. Journal of Graduate Medical Education, 2, 260–268.